Seroconversion and Kinetics of Vibriocidal Antibodies during the First 90 Days of Re-Vaccination with Oral Cholera Vaccine in an Endemic Population
Author:
Chisenga Caroline Cleopatra1ORCID, Phiri Bernard1, Ng’ombe Harriet1, Muchimba Mutinta1ORCID, Musukuma-Chifulo Kalo1ORCID, Silwamba Suwilanji1, Laban Natasha Makabilo1ORCID, Luchen Chaluma1, Liswaniso Fraser1ORCID, Chibesa Kennedy1ORCID, Mubanga Cynthia1ORCID, Mwape Kapambwe1, Simuyandi Michelo1ORCID, Cunningham Adam F.2, Sack David3, Bosomprah Samuel14ORCID
Affiliation:
1. Enteric Disease and Vaccine Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka P.O. Box 34681, Zambia 2. Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK 3. Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA 4. Department of Biostatistics, School of Public Health, University of Ghana, Accra P.O. Box LG13, Ghana
Abstract
Despite the successful introduction of oral cholera vaccines, Zambia continues to experience multiple, sporadic, and protracted cholera outbreaks in various parts of the country. While vaccines have been useful in staying the cholera outbreaks, the ideal window for re-vaccinating individuals resident in cholera hotspot areas remains unclear. Using a prospective cohort study design, 225 individuals were enrolled and re-vaccinated with two doses of Shanchol™, regardless of previous vaccination, and followed-up for 90 days. Bloods were collected at baseline before re-vaccination, at day 14 prior to second dosing, and subsequently on days 28, 60, and 90. Vibriocidal assay was performed on samples collected at all five time points. Our results showed that anti-LPS and vibriocidal antibody titers increased at day 14 after re-vaccination and decreased gradually at 28, 60, and 90 days across all the groups. Seroconversion rates were generally comparable in all treatment arms. We therefore conclude that vibriocidal antibody titers generated in response to re-vaccination still wane quickly, irrespective of previous vaccination status. However, despite the observed decline, the levels of vibriocidal antibodies remained elevated over baseline values across all groups, an important aspect for Zambia where there is no empirical evidence as to the ideal time for re-vaccination.
Funder
Bacterial Vaccines Network
Reference21 articles.
1. Ng’Ombe, H., Simuyandi, M., Mwaba, J., Luchen, C.C., Alabi, P., Chilyabanyama, O.N., Mubanga, C., Hatyoka, L.M., Muchimba, M., and Bosomprah, S. (2022). Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia. PLoS ONE, 17. 2. Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia;Mwaba;Vaccine,2021 3. Luchen, C.C., Mwaba, J., Ng’ombe, H., Alabi, P.I.O., Simuyandi, M., Chilyabanyama, O.N., Hatyoka, L.M., Mubanga, C., Bosomprah, S., and Chilengi, R. (2021). Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia. PLoS ONE, 16. 4. Chisenga, C.C., Bosomprah, S., Chilyabanyama, O.N., Alabi, P., Simuyandi, M., Mwaba, J., Ng’ombe, H., Laban, N.M., Luchen, C.C., and Chilengi, R. (2023). Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia. BMC Public Health, 23. 5. The Chronic Cholera Situation in Africa: Why Are African Countries Unable to Tame the Well-Known Lion?;Olu;Health Serv. Insights,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|